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Background
Hyperlipidaemia is an important risk factor for coronary heart disease. 1 There is compelling evidence about the effectiveness of lipid-lowering drugs in reducing lipid levels and reducing the risk of heart attacks and stroke. 2 Adherence is defined as the extent as to which patients take medication as prescribed and is determined by a variety of factors such as health beliefs, risk perception, poor knowledge, denial, adverse drug effects and poor memory. 3 The importance of the patient's agreement and the significance of the patient's role within the doctor-patient relationship have been emphasized, and compliance has been replaced by more patient-centred synonyms such as adherence and concordance. [4] [5] [6] High discontinuation rates and lack of adherence to cholesterol-lowering medication have been shown to be important factors in treatment failure in terms of achieving treatment goals as well as being associated with an increase in mortality. 7, 8 The treatment of a symptomless condition such as hyperlipidaemia signifies a particular challenge to both doctor and patient. Epidemiological data show that target cholesterol concentrations are only achieved in fewer than 50% of people receiving cholesterol-lowering drugs and that only one in four patients continued taking cholesterol-lowering drugs long-term. 9, 10 Primary prevention trials appear to have higher discontinuation rates than secondary prevention trials indicating a relationship between adherence and awareness of illness. 11, 12 The aim of this systematic review was to assess the effects of interventions designed to help people take their lipid-lowering medication in ambulatory settings.
Methods

Literature search
The search for original randomized controlled trials (RCTs) was conducted in November 2005 using a search developed by the Cochrane Heart Group. It included articles of all languages from any year in the Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library, MEDLINE, EMBASE, PsycInfo and CINAHL (Fig. 1) . In addition, we searched reference lists of retrieved papers and contacted study authors and experts in the field for additional information on further published and unpublished studies.
Study selection
Following the initial search, two reviewers selected studies independently by assessing titles and abstracts. Full-text articles of potential relevance were obtained. Following this initial screening, studies were selected by applying the following inclusion criteria:
Studies were RCTs, where care in the intervention group was compared to patients who received no intervention or usual care. Population of interest were adults prescribed lipidlowering medication for primary or secondary prevention of cardiovascular disease in ambulatory care settings. Interventions aimed to increase adherence to lipid-lowering medication, and were categorized as simplification of drug regimen, patient information and education, intensified patient care and complex behavioural approach. Outcomes were adherence to medication measured in the following ways: indirect measures (e.g. pill count, prescription refill rate, electronic monitoring), subjective measures (e.g. patients' self-report in diaries, interviews) and direct measures of adherence (tracer substances in blood or urine). Two additional outcomes were also recorded: physiological indicators (e.g. total cholesterol, low-density lipoprotein, high-density lipoprotein) and health outcome indications (e.g. quality of life, morbidity, mortality).
Data extraction
We extracted data using data collection forms. The form was developed and then piloted on a random sample of three studies. We contacted six study authors of original studies for clarification of details or further information, of whom five responded.
Data analysis
We grouped studies according to the type of intervention used and compared outcomes across these categories. We attempted to recalculate results where the reported data allowed this, using the Stata 8.0 statistical software package. 13 
Quality assessment
The four main sources of systematic bias (selection bias, performance bias, attrition bias and detection bias) were considered in the process of study assessment, as recommended by the Cochrane Reviewers' Handbook.
14 An overall assessment of the studies was performed by categorizing them into low risk of bias (if all of the above criteria were met), moderate risk of bias (one or more criteria only partly met) and high risk of bias (one or more criteria not met). 
FIGURE 1 Specific search terms
Results
Characteristics of included studies
The search contained 4254 articles, of which nine studies met all the inclusion criteria with a combined patient population of 6069 (Fig. 2) . Three of the included trials took place in primary care, [15] [16] [17] two in secondary care 18, 19 and one in both. 20 Other settings were local pharmacies, 21 health maintenance organizations 22 and veteran affairs medical centres 23 ( Table 1 ). The geographical settings included the USA (n = 6), Canada (n = 1) and Spain (n = 2). Of the four main classes of lipid-lowering drugs, no RCTs assessed adherence to fibrates, two RCTs to nicotinic acid/niacin drugs, 18, 23 three RCTs to anion-exchange resins 19, 20, 23 and six RCTs to statins. [15] [16] [17] 19, 21, 22 Patient morbidity ranged from participants with pre-existing cardiovascular pathology or increased cardiovascular risk 16, 18, 19 to healthy patients with high cholesterol levels 15, 17, 20 or both. [21] [22] [23] Follow-up time was generally short, ranging from 2 to 24 months.
Methodological quality
Few of the reported studies provided sufficient details on study design to assess methodological quality with confidence. None of the RCTs met all the methodological quality criteria and were therefore assessed as having moderate to high risk of bias. Blinding patients to the intervention they were receiving was not possible in this particular setting. Blinding of the health carer/doctor in order to avoid systematic differences in the care provided (performance bias) was attempted in two trials. 15, 19 Subgroup analyses, cluster randomized and cross-over designs were used without applying relevant statistical analysis.
18,21
Adherence and lipid outcomes There was substantial between-study heterogeneity in terms of population, class of lipid-lowering drugs used, measurement of adherence and length of follow-up, making pooling of data inappropriate. Baseline mean adherence levels were generally high (>80%) but fell substantially (<40%) at longer term follow-up (6-24 months). Physiological indicators of patient compliance such as serum lipids were only reported in five out of nine trials (Table 1) . 15, [17] [18] [19] [20] Simplification of drug regimen (two RCTs). No consistent pattern emerged in terms of improving adherence. Reducing drug intake from four times to twice daily improved adherence and serum lipids; mean medication intake was increased by 11% and mean total Potentially relevant publications identified via electronic search strategy, bibliographies, authors n=4254
RCTs included in the review n=9
Papers excluded scrolling through titles and abstracts due to lack of suitability (not concerned with blood lipids, not concerned with intervention, no RCT design) n=4158
Articles retrieved for more detailed information n=96
Excluded articles -reasons: not concerned with lipidaemia n=3 not a RCT design n=40 no interventions n=34 no adherence outcome n=9 not an ambulatory setting n=1 n=87
FIGURE 2 Progress of selecting papers through the review (search November 2005)
Family Practice-an international journal serum-cholesterol was decreased significantly by 14 mg/ dl. 18 Conversely, drug modification by administering cholestyramine bar instead of powder to make intake easier was not associated with improved adherence levels or improved lipid levels. 20 Patient information and education (two RCTs). There were improved effects on adherence in both RCTs. Videotapes, booklets and newspapers handed out by the local pharmacist followed by educational newsletters sent via post increased adherence by 13%. 21 The effect of the intervention was more substantial in the subgroup of patients taking newly initiated statins compared to those on repeat medication. 21 Another study applied a less personal approach by simply sending videotapes to members of a health maintenance organization, increasing adherence rates only slightly and non-significantly. 22 In both these trials, no data on effect of adherence on lipid levels were reported.
Intensified patient care (four RCTs). Intensified patient care in the form of telephone reminder as well as written material was associated with improved adherence in all four RCTs, with two RCTs reaching statistical significance. 17, 19 There was a positive but non-significant trend towards improvement in lipid levels in two studies. 17, 19 Complex behavioural approach. In a single RCT where participants attended small group training re-enforced with postal information, a non-significant improvement in adherence occurred, with a significant decrease in triglycerides of 30 mg/dl. 15 
Discussion
Principal findings This systematic review shows that there have been few RCTs that have examined the impact of adherenceenhancing interventions for lipid-lowering drugs. There is some evidence that intensified patient care, in the form of telephone reminders backed up with written information, improves patient adherence. The effect of these interventions appears to be greater on followup >6 months when adherence levels fall. This is not surprising as initially high adherence levels may reduce effect sizes and lead to underestimation of the intervention effect.
There is a paucity of evidence concerning the longer term effectiveness and cost-effectiveness of adherenceenhancing interventions and incomplete evidence concerning their effects on serum lipid levels. Treatment with statins was not associated with higher adherence levels ( Table 2 ). In the context of observational research suggesting that statins are better tolerated than other classes of lipid-lowering drugs, this was an unexpected finding most likely related to the relatively small number of trial participants.
Context
The indication for prescribing lipid-lowering drugs has changed substantially over the last 10 years. 2 With evidence to suggest that effectiveness of statins occurs irrespective of initial lipid level, greater numbers of people are being actively prescribed lipid-lowering agents. Observational studies have shown that adherence to lipid-lowering drugs is poor, with patients taking their medication only 60% of the time in a 1-year period. 24 There is strong evidence that adherence diminishes over time in patients who are being treated as part of a primary or secondary prevention strategy. 10, 12 The consequence of inadequate adherence to lipid-lowering therapy is substantial. In secondary prevention, inadequate adherence is associated with an increase in recurrent myocardial infarction and all cause mortality. 8 For these reasons, it is important that effective and cost-effective strategies to improve adherence are found for primary and secondary prevention of cardiovascular disease in the community.
Limitations
The difficulty in measuring adherence accurately and reliably is a significant limitation for any systematic review that seeks to assess the effectiveness of different adherence-enhancing strategies. Agreement on concerning the 'gold standard' for adherence measurement is difficult to find, with different measurement methods having different strengths and weaknesses. 25 Refill-records, patient self-report and pill count have been shown to overestimate adherence when compared to newer methods such as electronic monitoring of pill use or chemical markers. [26] [27] [28] Serum lipid measurement seems more reliable, but does not provide comparable data due to the impact of different medication and dosages on efficacy of lipid lowering. 29 As a result, the relationship between lipid levels and adherence is difficult to establish. A further limitation of this review is the relatively short duration of followup in all but one of the included RCTs. Observational studies have shown that adherence to lipid lowering falls substantially over time: the effectiveness of adherence-enhancing interventions may be more worthwhile during longer periods of follow-up.
Future research
The majority of interventions described in this review focus on only one or two aspects of adherence. However there are many factors-knowledge, health beliefs, risk perception, memory, side effects of medication, costs of medication and inconvenience that influence adherence to drugs. 3 The phenomenon of adherence is complex and it would seem reasonable for interventions to address this complexity with a more patient-centred approach. 2, 30 Patients' beliefs and preferences need to be acknowledged and incorporated into adherence-enhancing interventions. 6 A combination of strategies including information, reminding, adherence reinforcement and emphasis on the patient's perspective might lead to more effective adherence-enhancing strategies. In terms of lipidlowering drug class, the main focus should be on statins as they have been shown to be the most potent lipid-lowering drugs. 2 Other important aspects for future studies are that they include valid methods for measuring adherence, assess the effect on serum lipid levels and follow-up patients for a minimum of >12 months. Economic evaluation of the proposed intervention should also be performed.
Conclusion
In the context of increased prescribing of statins and changing indications for primary prevention, the issue of adherence to lipid-lowering drugs is an important public health issue. Evidence concerning effectiveness of adherence-enhancing strategies is sparse. Intensified patient care in the form of telephone reminders backed up with written information appears promising but requires further evaluation in terms of its effectiveness and cost effectiveness. to the authors of the original studies, BG Brown, E Bruckert, M Faulkner, E de Klerk, E Lesaffre and E Marquez-Contreras for their clarification and comments on their studies.
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